-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Early breast cancer patients need to choose a treatment option based on tumor characteristics, including tumor size, grade, hormone-like expression status, HER2 expression status, underarm lymph node status, and patient preferences.
growing evidence that genetic mutations in susceptible genes such as BRCA1 and BRCA2 are also linked to disease.
previous studies have shown that most breast cancers associated with BRCA2 mutations show ER-positive, while ER-positive is a favorable prognostic factor compared to ER-negative in the general early-stage patient population.
, however, recent studies have shown that ER-positive and low-level tumor status may not be good predictive of good prognostics in patients with BRCA2 mutations.
there are no studies to report the effects of various breast cancer treatment strategies on patients with BRCA2 mutations.
, the study aims to explore the effects of double ovary excision and other treatment strategies on survival rates in patients with BRCA2 mutant breast cancer.
10-year survival rate of BRCA2 mutant breast cancer patients analyzed 664 female BRCA2 mutant patients with stage I-III breast cancer by combining five different data sets (retrospective and forward-looking) studies.
from diagnosis to death, subjects were followed for an average of 7.2 years.
by analyzing the patient's tumor characteristics and cancer treatment records, and identifying relevant survival predictive factors with Cox regression models, and adjusting for other treatments and prognostic characteristics.
10-year breast cancer survival rate was 78.9 percent for ER-positive patients and 82.3 percent for ER-negative patients.
10-year breast cancer survival rate was 89.1 per cent for women who under performed a double-sided ovary excision, compared with 59.0 per cent for women who did not have a double-sided ovarian excision.
-adjusted chemotherapy risk ratio was 0.83.
10-year survival rate in patients with BRCA2 mutant breast cancer, the study revealed that ER-positive status did not indicate a higher survival rate for women with BRCA2 mutations with breast cancer.
ovarian excision is associated with a reduced risk of breast cancer death and should be considered in treatment plans.
